|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM203487265 |
| 003 |
DE-627 |
| 005 |
20231223230221.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231223s2011 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2010.10.001
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0678.xml
|
| 035 |
|
|
|a (DE-627)NLM203487265
|
| 035 |
|
|
|a (NLM)21062675
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Diamanti, Andrea Picchianti
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Reversion of resistance to immunosuppressive agents in three patients with psoriatic arthritis by cyclosporine A
|b modulation of P-glycoprotein function
|
| 264 |
|
1 |
|c 2011
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 08.03.2011
|
| 500 |
|
|
|a Date Revised 17.03.2022
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2010 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Secondary resistance may be a major problem in the management of autoimmune diseases. P-glycoprotein (P-gp) over-function has been described as a mechanism of drug resistance in autoimmune patients. P-gp function can in vitro be inhibited by cyclosporine A (CSA) and verapamil; moreover, P-gp reduction by CSA in systemic lupus erythematosus and rheumatoid arthritis has been demonstrated. Here, P-gp function before and after CSA administration in three psoriatic arthritis (PsA) patients, who developed a resistance to MTX/SSA, has been evaluated. P-gp function on patient cells was analyzed by measuring the changes in rhodamine-123 (Rh-123) fluorescence after verapamil incubation. CSA treatment resulted in good clinical outcome that was related with a significant P-gp function reduction at CD3+ and CD8+ levels. In addition to its immunosuppressive activity, CSA results may also be related to MTX/SSA effect restoration through P-gp inhibition. This is the first time that CSA has been demonstrated as being able to revert MTX/SSA resistance in PsA
|
| 650 |
|
4 |
|a Case Reports
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a ATP Binding Cassette Transporter, Subfamily B, Member 1
|2 NLM
|
| 650 |
|
7 |
|a CD3 Complex
|2 NLM
|
| 650 |
|
7 |
|a Immunosuppressive Agents
|2 NLM
|
| 650 |
|
7 |
|a Rhodamine 123
|2 NLM
|
| 650 |
|
7 |
|a 1N3CZ14C5O
|2 NLM
|
| 650 |
|
7 |
|a Sulfasalazine
|2 NLM
|
| 650 |
|
7 |
|a 3XC8GUZ6CB
|2 NLM
|
| 650 |
|
7 |
|a Cyclosporine
|2 NLM
|
| 650 |
|
7 |
|a 83HN0GTJ6D
|2 NLM
|
| 650 |
|
7 |
|a C-Reactive Protein
|2 NLM
|
| 650 |
|
7 |
|a 9007-41-4
|2 NLM
|
| 650 |
|
7 |
|a Verapamil
|2 NLM
|
| 650 |
|
7 |
|a CJ0O37KU29
|2 NLM
|
| 650 |
|
7 |
|a Methotrexate
|2 NLM
|
| 650 |
|
7 |
|a YL5FZ2Y5U1
|2 NLM
|
| 700 |
1 |
|
|a Rosado, Manuela
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Germano, Valentina
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Scarsella, Marco
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Giorda, Ezio
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Podestà, Edoardo
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a D'Amelio, Raffaele
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Carsetti, Rita
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Laganà, Bruno
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 138(2011), 1 vom: 13. Jan., Seite 9-13
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:138
|g year:2011
|g number:1
|g day:13
|g month:01
|g pages:9-13
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2010.10.001
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 138
|j 2011
|e 1
|b 13
|c 01
|h 9-13
|